Resilience Through-the-Scope Esophageal Stent now available in the US

Merit Medical announced the US commercial release of the Resilience Through-the-Scope Esophageal Stent on March 16, 2026; it is indicated for treatment of esophageal fistulas and strictures caused by malignant tumors.

Merit Medical announced the US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent. The device joins the company's Endoscopy portfolio as a treatment option for patients with disease of the esophagus. It is indicated for esophageal fistulas and strictures caused by malignant tumors. The release notes that esophageal cancer is a leading cause of cancer deaths worldwide and lists common symptoms such as trouble swallowing and chest pain. Key facts: - Announcement date: March 16, 2026, according to the company release. - Indicated for treatment of esophageal fistulas and malignant strictures. - Designed with proprietary anti-migration flanges and described as demonstrating the greatest migration resistance among currently available TTS stents. - Features a single-handed deployment system intended to aid clinicians in placement. - Offered in sizes 14 mm x 50 mm, 17 mm x 50 mm, and 20 mm x 50 mm. Summary: The launch expands Merit's endoscopy portfolio and presents a stent designed to address migration resistance and ease of placement. Undetermined at this time.